Dodkins Joanna, Cook Adrian, Mayne Emily, Parry Marina, Nossiter Julie, Payne Heather, Cowling Thomas E, Tree Alison, Aggarwal Ajay, Clarke Noel, van der Meulen Jan
Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.
National Cancer Audit Collaborating Centre, Royal College of Surgeons of England, London, UK.
BMJ Oncol. 2025 Apr 1;4(1):e000643. doi: 10.1136/bmjonc-2024-000643. eCollection 2025.
To evaluate the area-based incidence of metastatic prostate cancer at diagnosis, reflecting the risk of late-stage diagnosis, and overall prostate cancer incidence, reflecting the risk of over-diagnosis, in a country without a formal screening programme.
National study of annual prostate cancer incidence between 2015 and 2019. Mixed-effects regression estimated area-based incidence, adjusted for age, ethnicity and socioeconomic deprivation. Linear regression assessed the association between metastatic and overall cancer incidence.
National annual incidence of metastatic prostate cancer was 5.7 per 10 000 men and overall incidence was 43.9. Higher incidence of both metastatic and overall cancer were observed in areas with older populations and with more men with black ethnicity (both p<0.0001). Greater socioeconomic deprivation was linked to higher metastatic but lower overall cancer incidence (p<0.0001). Metastatic incidence varied across the country from 4.0 to 6.8, and prostate cancer overall from 37.9 to 50.1 per 10 000 men. Areas with higher metastatic cancer incidence had lower overall cancer incidence (p<0.0001).
There is significant geographic variation in metastatic prostate cancer incidence at diagnosis, with a higher incidence of metastatic cancer observed in areas with a lower overall prostate cancer incidence and in more socioeconomically deprived neighbourhoods, which likely contributes to poorer long-term outcomes. The findings highlight the need for a targeted, risk-based diagnostic approach as well as improved diagnostic facilities and referral pathways. Further research is needed to understand the factors driving this variation in order to reduce metastatic presentations and tackle inequalities in prostate cancer outcomes.
在一个没有正规筛查项目的国家,评估诊断时转移性前列腺癌的地区发病率(反映晚期诊断风险)以及前列腺癌总体发病率(反映过度诊断风险)。
对2015年至2019年期间前列腺癌年发病率进行全国性研究。混合效应回归估计地区发病率,并对年龄、种族和社会经济剥夺情况进行调整。线性回归评估转移性和总体癌症发病率之间的关联。
全国转移性前列腺癌的年发病率为每10000名男性中有5.7例,总体发病率为43.9例。在老年人口较多以及黑人男性较多的地区,转移性和总体癌症的发病率均较高(均p<0.0001)。社会经济剥夺程度越高,转移性癌症发病率越高,但总体癌症发病率越低(p<0.0001)。全国转移性发病率从每10000名男性中的4.0例到6.8例不等,前列腺癌总体发病率从37.9例到50.1例不等。转移性癌症发病率较高的地区总体癌症发病率较低(p<0.0001)。
诊断时转移性前列腺癌发病率存在显著的地理差异,在总体前列腺癌发病率较低以及社会经济剥夺程度较高的社区中,转移性癌症发病率较高,这可能导致较差的长期预后。研究结果凸显了需要采取有针对性的、基于风险的诊断方法以及改善诊断设施和转诊途径。需要进一步研究以了解导致这种差异的因素,从而减少转移性病例的出现并解决前列腺癌预后方面的不平等问题。